UC Irvine Researcher Confirms GenoMed's Patent-Pending Discovery:
ACE is Major Aging Gene, ACE Inhibition is Partial 'Fountain of Youth'
ST. LOUIS, Dec 13, 2004 /PRNewswire-FirstCall via COMTEX/ -- GenoMed, Inc.
(Pink Sheets: GMED), a Next Generation DM(TM) (Disease Management) company that
uses genomics to improve clinical outcomes, announced today that it's nearly
three-year old claim that angiotensin I-converting enzyme (ACE) is a major aging
gene in humans was independently corroborated by a researcher working at the
University of California at Irvine, Dr. Hamdi K. Hamdi.
GenoMed filed a patent application in February, 2002 claiming that inhibiting
ACE was part of the "Fountain of Youth." This claim was based on its finding
that most common diseases of aging were caused by a variant of the ACE gene
which led to overactivity of the enzyme. Dr. David Moskowitz, GenoMed's CEO,
published "Is ACE a 'Master' Disease Gene?" in October, 2002 in Diabetes
Technology and Therapeutics.
Publishing in Biochemical and Biophysical Research Communications, Dr. Hamdi and
colleagues showed in July, 2002 that the same variant of the ACE gene was
associated with age-related macular degeneration, a major cause of blindness in
the elderly. In October, 2003 and May, 2004, Dr. Hamdi and associates published
two critical papers showing that ACE inhibition in endothelial cells (the cells
that line the wall of blood vessels) induces prolonged survival and
immortalization factors that protect the cells from dying. Dr. Moskowitz has
published several papers on the molecular mechanism of action of the ACE enzyme.
Said Dr. David Moskowitz, GenoMed's CEO, "We are thrilled to have received
completely independent corroboration of our central hypothesis that ACE is a
major human aging gene. Dr. Hamdi's work in cell and molecular biology
complements our work at the molecular and clinical levels. What's even more
satisfying is that our intellectual property position is so strong. We are in an
excellent legal and business position to improve global public health. This is a
wonderful day for GenoMed, and a great day for everybody over the age of 40."
Said Dr. Hamdi of UC Irvine, "This is a revolutionary concept that will change
our view of disease and longevity."
About GenoMed
GenoMed is leading the clinical revolution which knowledge of the major aging
gene has already made possible. GenoMed is currently marketing its protocol for
preventing kidney failure due to high blood pressure and diabetes, and delaying
emphysema. The Company is collaborating on numerous additional clinical trials,
including one for influenza, since inhibiting ACE may work as a broad-spectrum
viral antidote. To enroll in one of GenoMed's free clinical trials, please email
dwmoskowitz@genomed.com.
SOURCE GenoMed, Inc.
CONTACT: David W. Moskowitz MD; CEO of GenoMed, Inc., +1-314-983-9933,
or dwmoskowitz@genomed.com; or Hamdi K. Hamdi PhD of UC Irvine, Department of
Medicine, +1-323-252-3021, or hhamdi@uci.edu
URL: genomedics.com
. |
